Markets are beset by volatility, with unpredictable swings making current periods one thing of a curler coaster. The principle indexes had been falling sharply on the finish of final week, however Friday’s launch of financial information exhibiting robust manufacturing exercise offered a lift that pared again the market losses considerably. The current earnings season additionally gave motive for optimism – the S&P listed corporations, collectively, reported 46% year-over-year earnings positive factors in Q1, in comparison with the 20% anticipated. Goldman Sachs strategist David Kostin sees the widely optimistic macro information offering help for equities in an unsure market surroundings. “The mixture of worldwide reopening, elevated shopper financial savings, and robust company working leverage will drive sharp recoveries in each financial and earnings development… U.S. equities will proceed to understand, albeit at a slower tempo than has characterised the previous 12 months… equities will stay enticing relative to money and bonds,” Kostin famous. Taking this into consideration, our consideration turned to a few shares that Goldman Sachs thinks have outsized development prospects, with the agency’s analysts forecasting over 100% upside potential for every. Utilizing TipRanks’ database, we discovered that the remainder of the Road can also be on board, as every boasts a “Robust Purchase” consensus score. Rain Therapeutics (RAIN) We’ll begin with a newly public biopharmaceutical firm Rain Therapeutics. The corporate is growing a tumor-agnostic remedy technique that selects sufferers primarily based on the underlying genetics somewhat than the histology of the illness. Rain has two drug candidates within the pipeline, RAIN-32, which is present process a number of scientific trials, and RAD52, which remains to be in preclinical trial. Taking a better take a look at the pipeline, we discover that RAIN-32, an MDM2 inhibitor referred to as milademetan, has a Part 3 trial for WD/DD liposarcoma scheduled to start within the second half of this yr. On the identical time, a Part 2 trial, an MDM2 basket research, can also be scheduled for 2H21. Past the WD/DD Part 3 and the Part 2 Basket research, the corporate can also be trying to provoke one other Part 2 research in intimal sarcoma by early 2022. RAD52, the corporate’s second pipeline candidate, is a novel method to the remedy of breast, prostate, pancreatic, and ovarian cancers. The drug remains to be in early analysis phases, however lead candidate choice for scientific research is ready to start someday subsequent yr. As talked about above, Rain is a newly public firm; it held its IPO in April of this yr. The corporate put 7,352,941 shares on the American public markets, at $17 every. The IPO raised about $125 million in gross proceeds. Opening protection of this inventory for Goldman Sachs, analyst Graig Suvannavejh writes: “Whereas we’re optimistic on RAIN-32’s prospects in LPS, the income alternative seems modest, as we challenge peak risk-unadj./adj. gross sales of $612mn/$428mn (assumes 70% POS), given simply c.3K in US annual incidence. That stated, our enthusiasm for RAIN additionally rests on RAIN-32’s potential past LPS, together with in intimal sarcoma (an extremely orphan most cancers), and in addition MDM2-amplified stable tumors, which we see as a considerable market alternative. Throughout these three, we challenge $2.2bn/$859mn in peak yr threat unadj./adj. gross sales within the US/EU5, with different future indications for RAIN-32 (trials to start out in 2022) and in addition a preclinical RAD52 program (an artificial lethality play) representing upside potential to our forecasts.” Consistent with his bullish stance, Suvannavejh charges RAIN a Purchase, and his $56 worth goal implies room for a shocking 252% upside potential within the subsequent 12 months. (To look at Suvannavejh’s observe report, click on right here) Turning now to the remainder of the Road, different analysts echo Suvannavejh’s sentiment. As solely Purchase suggestions have been revealed within the final three months, RAIN earns a Robust Purchase analyst consensus. With the typical worth goal clocking in at $33.75, shares may soar 112% from present ranges. (See RAIN inventory evaluation on TipRanks) Relmada Therapeutics (RLMD) The following inventory on Goldman Sachs’s radar, Relmada Therapeutics, is a clinical-stage pharmaceutical agency, which focuses on problems with the central nervous system. REL-1017, the corporate’s prime pipeline candidate, is a novel NMDA receptor channel blocker beneath improvement as a remedy for main depressive dysfunction. Psychological well being is a significant phase of the pharmaceutical business, and the antidepressant piece of the psychological well being pie is predicted to exceed $18.5 billion by 2027. Relmada began RELIANCE I, the primary pivotal trial of REL-1017, in December of final yr, testing the drug as an adjunctive remedy for main melancholy. By this previous April, two further research, RELIANCE II and RELIANCE-OPS had been underway. All three are actually ongoing, and a fourth, Part 1, research of REL-1017 as a monotherapy is ready to start within the first half of this yr. High-line information from the 2 pivotal research is scheduled for launch in 1H22. Goldman Sachs analyst Andrea Tan covers this inventory, and he or she offers it a Purchase score together with a $78 worth goal that means a 103% upside over the following 12 months. (To look at Tan’s observe report, click on right here) “We notice a string of key occasions in 2021+ that might drive worth inflection: (1) human abuse potential (HAP) research towards optimistic management oxycodone in 2Q21 and ketamine in 2H21, the place we see the market as pricing in an excessive amount of threat of a unfavorable final result (see state of affairs evaluation inside); (2) topline information for monotherapy REL-1017 in 4Q21; and (3) topline pivotal information in adjunctive MDD (GSe peak gross sales of $2.5bn in 2033) in 1H22 with NDA submission to comply with thereafter, all of which we’re constructive on given the differentiated profile demonstrating speedy onset of motion, enhanced efficacy, and good tolerability to-date,” Tan opined. What does the remainder of the Road should say? 3 Buys and no Holds or Sells add as much as a Robust Purchase consensus score. Given the $67.67 common worth goal, shares may climb 76% within the yr forward. (See RLMD inventory evaluation at TipRanks) Agiliti (AGTI) We’ll shut out our take a look at high-potential Goldman picks with Agiliti. The corporate is a supplier of medical tools, providing hospitals and well being programs a spread of bariatrics, beds, remedy mattresses, fall prevention units, ventilators, breast pumps, affected person screens, medical-grade adjustable chairs, and surgical tools – together with the technical help, scientific engineering, and on-site administration to correctly use, keep, and modify the myriad units. By the numbers, Agiliti boasts over 90 service facilities throughout the decrease 48 states, supporting greater than 800,000 items of medical tools in over 7,000 acute care hospitals and alternate medical websites. On April 23 of this yr, Agility debuted its inventory on the NYSE in an IPO that was initially priced at $14. The corporate put over 26.3 million shares in the marketplace, and raised roughly $431.5 million in gross proceeds within the first day of the IPO. Final week, Agiliti launched its first quarterly monetary report as a public firm. The highest line income, at $235 million, was 31% greater than the year-ago Q1. Web earnings was $9.6 million, up a robust $22.2 million from final yr’s Q1 internet loss, and EPS was 9 cents per share. Trying on the firm’s ahead path, Goldman Sachs analyst Amit Hazan famous, “Whereas not mirrored within the 1Q shut steadiness sheet, administration offered visibility to post-IPO leverage of roughly 3.3x on a pro-forma foundation. Whereas considerably constrained from a managerial standpoint given calls for from Northfield, administration expects each the monetary and managerial flexibility to pursue opportunistic M&A by later this yr.” Hazan summed up, “We view AGTI’s end-to-end service mannequin as differentiated and ideally suited in as we speak’s Hospital working surroundings; we see present valuation as a horny entry level…” To this finish, Hazan offers AGTI shares a Purchase score, and his $43 worth goal implies a 151% upside for the approaching yr. (To look at Hazan’s observe report, click on right here) In its first few weeks on the general public markets, AGTI shares have picked up 9 opinions, which embody 8 Buys and simply 1 Maintain. The inventory is promoting for $17.12 and the $21.39 common worth goal suggests it has room for ~25% one-year upside potential. (See AGTI inventory evaluation on TipRanks) To seek out good concepts for shares buying and selling at enticing valuations, go to TipRanks’ Greatest Shares to Purchase, a newly launched device that unites all of TipRanks’ fairness insights. Disclaimer: The opinions expressed on this article are solely these of the featured analysts. The content material is meant for use for informational functions solely. It is rather necessary to do your personal evaluation earlier than making any funding.